Compositions and Methods for Reducing Respiratory Depression and Attendant SIde Effects of Mu Opioid Compounds
申请人:Ardent Pharmaceuticals, Inc.
公开号:US20020111359A1
公开(公告)日:2002-08-15
Abstract of Disclosure
A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound. Preferred examples of such delta receptor agonist compound include diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy for reducing respiratory depression associated with certain analgesics, such as mu opiates.
本发明涉及一种减少、治疗或预防动物在接受混合的δ/μ阿片受体激动剂或呼吸抑制介导药物时出现的呼吸抑制、肌肉僵硬或恶心/呕吐的方法,包括向接受该药物的动物投与有效量的δ受体激动剂化合物。此类δ受体激动剂化合物的优选例子包括二芳基甲基哌嗪化合物和二芳基甲基哌啶化合物及其制药组合物,具有在医学治疗中减少与某些镇痛药物(如μ阿片类)相关的呼吸抑制的功效。